Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645220 | 0.87 | PDE2A (0.36) | BRPF1PPARGS1PR1LMNA | |
| SCHEMBL1643362 | 0.87 | MCHR1 (0.35) | BRPF1PPARGTAS1R3TAS1R1ROCK2 | |
| SCHEMBL1643380 | 0.86 | MAPT (0.38) | BRPF1PPARG | |
| SCHEMBL1284794 | 0.86 | NPC1 (0.34) | BRPF1PPARGS1PR1S1PR3ROCK2 | |
| SCHEMBL1643883 | 0.85 | PDE2A (0.33) | BRPF1PPARGTAS1R3TAS1R1S1PR1 | |
| SCHEMBL1645194 | 0.84 | HDAC3 (0.41) | IDO1KCNH2 | |
| SCHEMBL1644603 | 0.83 | MEN1 (0.37) | TAS1R3TAS1R1ROCK2ROCK1NPC1 | |
| SCHEMBL1643550 | 0.81 | LMNA (0.39) | PPARGS1PR1S1PR3NPC1ALDH1A1 | |
| SCHEMBL1644460 | 0.81 | NR1H4 (0.38) | PPARGALDH1A1LMNA | |
| SCHEMBL1645409 | 0.81 | PDE2A (0.44) | PPARGTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | BRPF1 2308/4885IDO1 3128/4885KCNH2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.